Risk factors that affect life expectancy in alzheimer's disease: A 15-year follow-up

Dementia and Geriatric Cognitive Disorders

Volumn 38, Issue 5-6, 2014, Pages 286-299

  Wattmo, Carina ^a   Londos, Elisabet ^a   Minthon, Lennart ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein E genotype; Cholinesterase inhibitors; Level of education; Longitudinal study; Mortality

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGE AT DEATH; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COGNITION; DAILY LIFE ACTIVITY; DEATH; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENOTYPE; HUMAN; LIFE EXPECTANCY; LIFESPAN; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; OBSERVATIONAL STUDY; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; SOCIOECONOMICS; SURVIVAL RATE; SWEDEN; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; SWEDEN;

EID: 84908146602     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000362926     Document Type: Article

References (45)

1. Fratiglioni L, De Ronchi D, Aguero-Torres H: Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15: 365-375.
2. Wortmann M: Dementia: a global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 2012; 4: 40.
3. Alzheimer's Disease International: World Alzheimer Report 2010. The Global Economic Impact of Dementia; in Wimo A, Prince M (eds). London, 2010, pp 1-56.
4. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A: Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-973.
5. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995; 45: 1451-1455.
6. Brookmeyer R, Corrada MM, Curriero FC, Kawas C: Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002; 59: 1764-1767.
7. Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y: Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology 2008; 71: 1489-1495.
8. Statistiska centralbyrån, Sverige (Statistics Sweden): Life tables 2008-2012. http://www.scb.se/Pages/ProductTables-25809.aspx (accessed July 22, 2013).
9. Gasper MC, Ott BR, Lapane KL: Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother 2005; 3: 1-7.
10. Rountree SD, Chan W, Pavlik VN, Darby EJ, Doody RS: Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther 2012; 4: 16.
11. Brodaty H, Seeher K, Gibson L: Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr 2012; 24: 1034-1045.
12. Barclay LL, Zemcov A, Blass JP, McDowell FH: Factors associated with duration of survival in Alzheimer's disease. Biol Psychiatry 1985;20:86-93.
13. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA: Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501-509.
14. Bonsignore M, Heun R: Mortality in Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15:231-236.
15. Stern Y, Tang MX, Denaro J, Mayeux R: Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995; 37: 590-595.
16. Tilvis RS, Strandberg TE, Juva K: Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. J Am Geriatr Soc 1998; 46: 712-715.
17. Walsh JS, Welch HG, Larson EB: Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990; 113: 429-434.
18. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L: Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-160.
19. Wattmo C, Wallin AK, Londos E, Minthon L: Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther 2011; 3: 23.
20. Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L: Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement Geriatr Cogn Disord 2008; 26: 203-211.
21. Wattmo C, Wallin AK, Londos E, Minthon L: Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontol-ogist 2011; 51: 17-27.
22. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
23. Frances A, American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV: prepared by the Task Force on DSM-IV, ed 4. Washington, American Psychiatric Association, 1994.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
25. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
26. Statistiska centralbyrån, Sverige (Statistics Sweden): Statistisk årsbok för Sverige 1999 (Statistical Yearbook of Sweden 1999). Stockholm, 1999.
27. Statistiska centralbyrån, Sverige (Statistics Sweden): Statistisk årsbok för Sverige 2004 (Statistical Yearbook of Sweden 2004). Stockholm, 2004.
28. Statistiska centralbyrån, Sverige (Statistics Sweden): Statistisk årsbok för Sverige 2009 (Statistical Yearbook of Sweden 2009). Stockholm, 2009.
29. Stern Y, Albert S, Tang MX, Tsai WY: Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 1999; 53: 1942-1947.
30. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barnes LL, Bienias JL: Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003; 60: 1909-1915.
31. Bruandet A, Richard F, Bombois S, Maurage CA, Masse I, Amouyel P, Pasquier F: Cognitive decline and survival in Alzheimer's disease according to education level. Dement Geriatr Cogn Disord 2008; 25: 74-80.
32. Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992; 42: 1689-1696.
33. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-221.
34. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B: Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc 1998; 46: 444-452.
35. Lagergren M: The systems of care for frail elderly persons: the case of Sweden. Aging Clin Exp Res 2002; 14: 252-257.
36. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19: 321-322.
37. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB: Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998; 51: 149-153.
38. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C: Apolipo-protein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006; 22: 73-82.
39. Rasmusson DX, Carson KA, Brookmeyer R, Kawas C, Brandt J: Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn 1996; 31: 133-147.
40. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, Marder K, Sano M, Albert S, Del-Castillo Castenada C, Bylsma F, Tycko B, Mayeux R: The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41: 615-620.
41. Beydoun MA, Beydoun HA, Kaufman JS, An Y, Resnick SM, O'Brien R, Ferrucci L, Zonderman AB: Apolipo-protein E epsilon4 allele interacts with sex and cognitive status to influence all-cause and cause-specific mortality in US older adults. J Am Geriatr Soc 2013; 61: 525-534.
42. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, Kremer D, van der Breggen R, Suchiman HE, Lakenberg N, van den Akker EB, Passtoors WM, Tiemeier H, van Heemst D, de Craen AJ, Rivadeneira F, de Geus EJ, Perola M, van der Ouderaa FJ, Gunn DA, Boomsma DI, Uitterlinden AG, Christensen K, van Duijn CM, Heijmans BT, Houwing-Duistermaat JJ, Westendorp RG, Slagboom PE: Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 2011; 10: 686-698.
43. Nebel A, Kleindorp R, Caliebe A, Nothnagel M, Blanche H, Junge O, Wittig M, Ellinghaus D, Flachsbart F, Wichmann HE, Meitinger T, Nikolaus S, Franke A, Krawczak M, Lathrop M, Schreiber S: A genome-wide association study confirms APOE as the major gene influencing survival in long-lived individuals. Mech Ageing Dev 2011; 132: 324-330.
44. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF: Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001; 154: 642-648.
45. Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y: Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005; 62: 1601-1608.